The burgeoning landscape of treatment for excess body fat and type 2 diabetes is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant differences in their pharmacological profiles and clinical trial results are emerging. Retatrutide, boa

Retaglutide and tirzepatide represent cutting-edge category of medications known as dual GLP-1 and GIP agonists. These agents target both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that have a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones